Health state utility values in patients with schizophrenia: a systematic review_Chinese Journal of Evidence-Based Medicine

Authors：

WANG Pei , ZHANG Xinxin ,  CHEN Lei

Research Center of National Drug Policy & Ecosystem, China Pharmaceutical University, Nanjing 211198, P. R. China;

Corresponding author：

CHEN Lei, Email: cpuchenlei@qq.com

Keywords：

Schizophrenia; Health state utility value; Quality of life; Systematic review; Meta-analysis

DOI：

10.7507/1672-2531.202207102

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the health state utility values in patients with schizophrenia, and to provide references for subsequent studies on the health economics of schizophrenia. Methods The PubMed, EMbase, The Cochrane Library, Web of Science, CNKI, WanFang Data, and VIP databases were searched from inception to December 1^st, 2021 to collect studies on health state utility values in patients with schizophrenia. Two reviewers independently screened literature, extracted data, and assessed the risk of bias of the included studies. Meta-analysis was then performed by Stata 15.0 software. Results A total of 19 studies were included. Patients’ utility values were 0.68 (95%CI 0.59 to 0.77) for direct measures, and 0.77 (95%CI 0.75 to 0.80) and 0.66 (95%CI 0.61 to 0.70) for indirect measures with the EQ-5D-5L and EQ-5D-3L as the primary scales. Utility values varied with measures, tariffs, regions, and populations. Conclusion Studies on health state utility value in schizophrenia are diversified in measurement methods, showing high inter-study heterogeneity. Therefore, it is necessary to promote the study on utility value measurement in schizophrenia in China.

Citation： WANG Pei, ZHANG Xinxin, CHEN Lei. Health state utility values in patients with schizophrenia: a systematic review. Chinese Journal of Evidence-Based Medicine, 2023, 23(1): 50-58. doi: 10.7507/1672-2531.202207102 Copy

1.	赵靖平, 施慎逊. 中国精神分裂症防治指南(第二版). 北京: 中华医学电子音像出版社, 2015.
2.	黄源, 刘国恩, 刘跃华, 等. 精神分裂症的疾病经济负担: 基于广州医保数据的分析. 中国卫生经济, 2014, 33(5): 62-65.
3.	Phillips D. Quality of life: concept, policy and practice. Oxfordshire: Routledge, 2006.
4.	王倩, 林果为, 徐三荣. 慢性胃炎, 消化性溃疡和胃癌的健康效用值的测定. 中华消化杂志, 2000, 20(4): 273-274.
5.	Deummonnd MF, O' brien BJ, Stoddart GL, et al. Methods for economic evaluation of health care programmes (2nd editon). Oxford: Oxford University Press, 1997.
6.	官海静, 刘国恩. 中国四地城乡居民生命质量的比较分析. 中国卫生经济, 2015, 34(2): 5-12.
7.	Aceituno D, Pennington M, Iruretagoyena B, et al. Health state utility values in schizophrenia: a systematic review and meta-analysis. Value Health, 2020, 23(9): 1256-1267.
8.	Papaioannou D, Brazier J, Paisley S. NICE DSU technical support document 9: the identification, review and synthesis of health state utility values from the literature. Available at: https://www.ncbi.nlm.nih.gov/books/NBK425822/pdf/Bookshelf_NBK425822.pdf.
9.	Brazier J, Ara R, Azzabi I, et al. Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR good practices for outcomes research task force report. Value Health, 2019, 22(3): 267-275.
10.	张天嵩, 董圣杰, 周支瑞. 高级 Meta 分析方法: 基于Stata实现. 上海: 复旦大学出版社, 2015.
11.	Lenert LA, Ziegler J, Lee T, et al. Differences in health values among patients, family members, and providers for outcomes in schizophrenia. Med Care, 2000, 38(10): 1011-1021.
12.	Voruganti LN, Awad AG, Oyewumi LK, et al. Assessing health utilities in schizophrenia: a feasibility study. Pharmacoeconomics, 2000, 17(3): 273-286.
13.	Oh PI, Lanctôt KL, Mittmann N, et al. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ, 2001, 4(1-4): 137-156.
14.	Kasckow JW, Twamley E, Mulchahey JJ, et al. Health-related quality of well-being in chronically hospitalized patients with schizophrenia: comparison with matched outpatients. Psychiatry Res, 2001, 103(1): 69-78.
15.	Dernovsek MZ, Prevolnik Rupel V, Rebolj M, et al. Quality of life and treatment costs in schizophrenic outpatients, treated with depot neuroleptics. Eur Psychiatry, 2001, 16(8): 474-482.
16.	Prieto L, Sacristán JA. What is the value of social values. The uselessness of assessing health-related quality of life through preference measures. BMC Med Res Methodol, 2004, 4: 10.
17.	van de Willige G, Wiersma D, Nienhuis FJ, et al. Changes in quality of life in chronic psychiatric patients: a comparison between EuroQol (EQ-5D) and WHOQoL. Qual Life Res, 2005, 14(2): 441-451.
18.	Luo N, Seng BK, Thumboo J, et al. A study of the construct validity of the health utilities index mark 3 (HUI3) in patients with schizophrenia. Qual Life Res, 2006, 15(5): 889-898.
19.	Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes, 2008, 6: 105.
20.	König HH, Günther OH, Angermeyer MC, et al. Utility assessment in patients with mental disorders: validity and discriminative ability of the time trade-off method. Pharmacoeconomics, 2009, 27(5): 405-419.
21.	McCrone P, Patel A, Knapp M, et al. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. J Ment Health Policy Econ, 2009, 12(1): 27-31.
22.	Alonso J, Croudace T, Brown J, et al. Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the schizophrenia health outcomes (SOHO) study. Value Health, 2009, 12(4): 536-543.
23.	Thwin SS, Hermes E, Lew R, et al. Assessment of the minimum clinically important difference in quality of life in schizophrenia measured by the quality of well-being scale and disease-specific measures. Psychiatry Res, 2013, 209(3): 291-296.
24.	Millier A, Amri I, Boyer L, et al. Utility decrements associated with side effects in schizophrenia. J Med Econ, 2014, 17(12): 853-861.
25.	Wijnen BFM, Pos K, Velthorst E, et al. Economic evaluation of brief cognitive behavioural therapy for social activation in recent-onset psychosis. PLoS One, 2018, 13(11): e0206236.
26.	Holt RI, Hind D, Gossage-Worrall R, et al. Structured lifestyle education to support weight loss for people with schizophrenia, schizoaffective disorder and first episode psychosis: the STEPWISE RCT. Health Technol Assess, 2018, 22(65): 1-160.
27.	Abdin E, Chong SA, Seow E, et al. A comparison of the reliability and validity of SF-6D, EQ-5D and HUI3 utility measures in patients with schizophrenia and patients with depression in Singapore. Psychiatry Res, 2019, 274: 400-408.
28.	Chan HY, Wijnen BFM, Hiligsmann M, et al. Assessment of quality of life 8-dimension (AQoL-8D): translation, validation, and application in two Dutch trials in patients with epilepsy and schizophrenia. Expert Rev Pharmacoecon Outcomes Res, 2022, 22(5): 795-803.
29.	Purba FD, Anggriani Y, Murtini T. EQ-5D-5L in schizophrenia: differences between patients and nurses' reports. Health Qual Life Outcomes, 2021, 19(1): 240.
30.	Spilker B. Quality of life and pharmacoeconomics in clinical trials (2nd edition). New York: Raven Press, 1996.
31.	Versteegh MM, Vermeulen KM, Evers SM, et al. Dutch tariff for the five-level version of EQ-5D. Value Health, 2016, 19(4): 343-352.
32.	Devlin NJ, Shah KK, Feng Y, et al. Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Econ, 2018, 27(1): 7-22.
33.	Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ, 2002, 21(2): 271-292.
34.	van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health, 2012, 15(5): 708-715.
35.	Luo N, Wang P, Thumboo J, et al. Valuation of EQ-5D-3L health states in Singapore: modeling of time trade-off values for 80 empirically observed health states. Pharmacoeconomics, 2014, 32(5): 495-507.
36.	Horsman J, Furlong W, Feeny D, et al. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes, 2003, 1: 54.
37.	Lamers LM, McDonnell J, Stalmeier PF, et al. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ, 2006, 15(10): 1121-1132.
38.	Richardson J, Sinha K, Iezzi A, et al. Modelling utility weights for the Assessment of Quality of Life (AQoL)-8D. Qual Life Res, 2014, 23(8): 2395-2404.
39.	Devlin NJ, Brooks R. EQ-5D and the EuroQol Group: past, present and future. Appl Health Econ Health Policy, 2017, 15(2): 127-137.
40.	Brazier JE, Yang Y, Tsuchiya A, et al. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ, 2010, 11(2): 215-225.
41.	Earnshaw J, Lewis G. NICE guide to the methods of technology appraisal: pharmaceutical industry perspective. Pharmacoeconomics, 2008, 26(9): 725-727.
42.	任雪英, 张建方, 占建华, 等. 社会心理干预对精神分裂症患者药物治疗的成本-效果分析. 医院管理论坛, 2019, 36(9): 38-40,15.
43.	朱晓晨, 陈彦瑾, 韩晟. 哌罗匹隆治疗精神分裂症的药物经济学评价——基于主要不良事件的研究. 中国药房, 2021, 32(10): 1252-1256.
44.	刘凤斌, 赵利, 郎建英, 等. 中华生存质量量表的研制. 中国组织工程研究与临床康复, 2007, (52): 10492-10495,10515.
45.	Ng SM, Yau JK, Chan CL, et al. The measurement of body-mind-spirit well-being toward multidimensionality and transcultural applicability. Soc Work Health Care, 2005, 41(1): 33-52.

1. 赵靖平, 施慎逊. 中国精神分裂症防治指南(第二版). 北京: 中华医学电子音像出版社, 2015.
2. 黄源, 刘国恩, 刘跃华, 等. 精神分裂症的疾病经济负担: 基于广州医保数据的分析. 中国卫生经济, 2014, 33(5): 62-65.
3. Phillips D. Quality of life: concept, policy and practice. Oxfordshire: Routledge, 2006.
4. 王倩, 林果为, 徐三荣. 慢性胃炎, 消化性溃疡和胃癌的健康效用值的测定. 中华消化杂志, 2000, 20(4): 273-274.
5. Deummonnd MF, O' brien BJ, Stoddart GL, et al. Methods for economic evaluation of health care programmes (2nd editon). Oxford: Oxford University Press, 1997.
6. 官海静, 刘国恩. 中国四地城乡居民生命质量的比较分析. 中国卫生经济, 2015, 34(2): 5-12.
7. Aceituno D, Pennington M, Iruretagoyena B, et al. Health state utility values in schizophrenia: a systematic review and meta-analysis. Value Health, 2020, 23(9): 1256-1267.
8. Papaioannou D, Brazier J, Paisley S. NICE DSU technical support document 9: the identification, review and synthesis of health state utility values from the literature. Available at: https://www.ncbi.nlm.nih.gov/books/NBK425822/pdf/Bookshelf_NBK425822.pdf.
9. Brazier J, Ara R, Azzabi I, et al. Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR good practices for outcomes research task force report. Value Health, 2019, 22(3): 267-275.
10. 张天嵩, 董圣杰, 周支瑞. 高级 Meta 分析方法: 基于Stata实现. 上海: 复旦大学出版社, 2015.
11. Lenert LA, Ziegler J, Lee T, et al. Differences in health values among patients, family members, and providers for outcomes in schizophrenia. Med Care, 2000, 38(10): 1011-1021.
12. Voruganti LN, Awad AG, Oyewumi LK, et al. Assessing health utilities in schizophrenia: a feasibility study. Pharmacoeconomics, 2000, 17(3): 273-286.
13. Oh PI, Lanctôt KL, Mittmann N, et al. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ, 2001, 4(1-4): 137-156.
14. Kasckow JW, Twamley E, Mulchahey JJ, et al. Health-related quality of well-being in chronically hospitalized patients with schizophrenia: comparison with matched outpatients. Psychiatry Res, 2001, 103(1): 69-78.
15. Dernovsek MZ, Prevolnik Rupel V, Rebolj M, et al. Quality of life and treatment costs in schizophrenic outpatients, treated with depot neuroleptics. Eur Psychiatry, 2001, 16(8): 474-482.
16. Prieto L, Sacristán JA. What is the value of social values. The uselessness of assessing health-related quality of life through preference measures. BMC Med Res Methodol, 2004, 4: 10.
17. van de Willige G, Wiersma D, Nienhuis FJ, et al. Changes in quality of life in chronic psychiatric patients: a comparison between EuroQol (EQ-5D) and WHOQoL. Qual Life Res, 2005, 14(2): 441-451.
18. Luo N, Seng BK, Thumboo J, et al. A study of the construct validity of the health utilities index mark 3 (HUI3) in patients with schizophrenia. Qual Life Res, 2006, 15(5): 889-898.
19. Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes, 2008, 6: 105.
20. König HH, Günther OH, Angermeyer MC, et al. Utility assessment in patients with mental disorders: validity and discriminative ability of the time trade-off method. Pharmacoeconomics, 2009, 27(5): 405-419.
21. McCrone P, Patel A, Knapp M, et al. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. J Ment Health Policy Econ, 2009, 12(1): 27-31.
22. Alonso J, Croudace T, Brown J, et al. Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the schizophrenia health outcomes (SOHO) study. Value Health, 2009, 12(4): 536-543.
23. Thwin SS, Hermes E, Lew R, et al. Assessment of the minimum clinically important difference in quality of life in schizophrenia measured by the quality of well-being scale and disease-specific measures. Psychiatry Res, 2013, 209(3): 291-296.
24. Millier A, Amri I, Boyer L, et al. Utility decrements associated with side effects in schizophrenia. J Med Econ, 2014, 17(12): 853-861.
25. Wijnen BFM, Pos K, Velthorst E, et al. Economic evaluation of brief cognitive behavioural therapy for social activation in recent-onset psychosis. PLoS One, 2018, 13(11): e0206236.
26. Holt RI, Hind D, Gossage-Worrall R, et al. Structured lifestyle education to support weight loss for people with schizophrenia, schizoaffective disorder and first episode psychosis: the STEPWISE RCT. Health Technol Assess, 2018, 22(65): 1-160.
27. Abdin E, Chong SA, Seow E, et al. A comparison of the reliability and validity of SF-6D, EQ-5D and HUI3 utility measures in patients with schizophrenia and patients with depression in Singapore. Psychiatry Res, 2019, 274: 400-408.
28. Chan HY, Wijnen BFM, Hiligsmann M, et al. Assessment of quality of life 8-dimension (AQoL-8D): translation, validation, and application in two Dutch trials in patients with epilepsy and schizophrenia. Expert Rev Pharmacoecon Outcomes Res, 2022, 22(5): 795-803.
29. Purba FD, Anggriani Y, Murtini T. EQ-5D-5L in schizophrenia: differences between patients and nurses' reports. Health Qual Life Outcomes, 2021, 19(1): 240.
30. Spilker B. Quality of life and pharmacoeconomics in clinical trials (2nd edition). New York: Raven Press, 1996.
31. Versteegh MM, Vermeulen KM, Evers SM, et al. Dutch tariff for the five-level version of EQ-5D. Value Health, 2016, 19(4): 343-352.
32. Devlin NJ, Shah KK, Feng Y, et al. Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Econ, 2018, 27(1): 7-22.
33. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ, 2002, 21(2): 271-292.
34. van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health, 2012, 15(5): 708-715.
35. Luo N, Wang P, Thumboo J, et al. Valuation of EQ-5D-3L health states in Singapore: modeling of time trade-off values for 80 empirically observed health states. Pharmacoeconomics, 2014, 32(5): 495-507.
36. Horsman J, Furlong W, Feeny D, et al. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes, 2003, 1: 54.
37. Lamers LM, McDonnell J, Stalmeier PF, et al. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ, 2006, 15(10): 1121-1132.
38. Richardson J, Sinha K, Iezzi A, et al. Modelling utility weights for the Assessment of Quality of Life (AQoL)-8D. Qual Life Res, 2014, 23(8): 2395-2404.
39. Devlin NJ, Brooks R. EQ-5D and the EuroQol Group: past, present and future. Appl Health Econ Health Policy, 2017, 15(2): 127-137.
40. Brazier JE, Yang Y, Tsuchiya A, et al. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ, 2010, 11(2): 215-225.
41. Earnshaw J, Lewis G. NICE guide to the methods of technology appraisal: pharmaceutical industry perspective. Pharmacoeconomics, 2008, 26(9): 725-727.
42. 任雪英, 张建方, 占建华, 等. 社会心理干预对精神分裂症患者药物治疗的成本-效果分析. 医院管理论坛, 2019, 36(9): 38-40,15.
43. 朱晓晨, 陈彦瑾, 韩晟. 哌罗匹隆治疗精神分裂症的药物经济学评价——基于主要不良事件的研究. 中国药房, 2021, 32(10): 1252-1256.
44. 刘凤斌, 赵利, 郎建英, 等. 中华生存质量量表的研制. 中国组织工程研究与临床康复, 2007, (52): 10492-10495,10515.
45. Ng SM, Yau JK, Chan CL, et al. The measurement of body-mind-spirit well-being toward multidimensionality and transcultural applicability. Soc Work Health Care, 2005, 41(1): 33-52.

Chinese Journal of Evidence-Based Medicine

Health state utility values in patients with schizophrenia: a systematic review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content